Objective: To determine the effectiveness of therapy with basal insulin analogs administered in poorly controlled type 2 diabetes mellitus patients switching from oral antidiabetic drugs with or without NPH insulin. Patients and methods: Observational retrospective study carried out in 250 type 2 diabetes mellitus patients who switched from oral antidiabetic drugs with or without insulin NPH to...

BACKGROUND To investigate the costs of treatment with basal insulin (insulin NPH [NPH], insulin glargine [IG], insulin determir [IG]), and premixed insulin (PM) in routine clinical care. METHODS Cohort study based on data from the Swedish National Diabetes Register, including 5077 insulin-naïve men and women with type 2 diabetes, resident in a distinct geographical region of Sweden. Patients ...

AIMS To compare the risk of vascular disease, HbA1c and weight change, between first prescribed insulins in people with type 2 diabetes. METHODS People included in THIN United Kingdom primary care record database who began insulin (2000-2007) after poor control on oral glucose-lowering agents (OGLD) were grouped by the number of OGLDs in their treatment regimen immediately before starting ins...

BACKGROUND Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. We compared the incidence of cancer in new users of glargine versus new users of NPH in a longitudinal clinical cohort with diabetes for up to 6 years. METHODS AND FINDINGS From all patients who had been regularly followed at Massachusetts General Hospital from 1/01/2005 to 12/31/2...

AIMS Insulin is normally added to oral glucose-lowering drugs in people with type 2 diabetes when glycaemic control becomes suboptimal. We evaluated outcomes in people starting insulin therapy with neutral protamine Hagedorn (NPH), detemir, glargine or premixed insulins. METHODS Insulin-naïve people with type 2 diabetes (n = 8009), ≥ 35 years old, HbA(1c) ≥ 6.5% and begun on NPH (n = 1463), d...

AIM To compare the safety and efficacy or 3 basal-bolus regimens of neutral protamine hagedorn (NPH)/regular insulin in the management of inpatient hyperglycemia. METHODS We randomized 105 patients with blood glucose levels between 140 and 400 mg/dL to a basal-bolus regimen of NPH insulin given once (n = 30), twice (n = 40) or three times (n = 35) daily, in addition to pre-meal regular insuli...

OBJECTIVE Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin. RESEARCH DESIGN AND METHODS In total, 876 relatively well-controlled patients with type 2 diabetes (mean HbA1c 7.55%) were randomized and treated with glulisine/NPH ...

OBJECTIVE To compare the efficacy and safety of a concentrated formulation of insulin glargine (Gla-300) with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM). DESIGN This was a network meta-analysis (NMA) of randomised clinical trials of basal insulin therapy in T2DM identified via a systematic literature review of Cochrane library databases, MEDLINE and MEDLINE...

c The ADA/EASD statement lists regular and NPH insulins before the longand rapid-acting insulin analogs (Table 1 in ref. [2]), and does not indicate a preference for insulin analogs despite greater nocturnal hypoglycemia with NPH and reduced postprandial fluctuation with the rapid-acting analogs. AACE/ACE indicates strong preferences for the insulin analogs in view of their reduced risk of hypo...

OBJECTIVE Appropriate treatment of patients with Type 1 diabetes mellitus (T1DM) is necessary to avoid further complications. This study was performed to compare the efficacy of insulin Glargine and Aspart with NPH insulin and regular insulin regimen in a group of children with T1DM. METHODS Forty patients with T1DM were enrolled in this study. During run-in, all subjects were treated with co...